Idorsia Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDRSF research report →
Companywww.idorsia.com
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc.
- CEO
- Jean-Paul Clozel
- IPO
- 2017
- Employees
- 1,100
- HQ
- Allschwil, CH
Price Chart
Valuation
- Market Cap
- $1.45B
- P/E
- -4.57
- P/S
- 3.92
- P/B
- -0.86
- EV/EBITDA
- -14.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.88%
- Op Margin
- -95.64%
- Net Margin
- -100.74%
- ROE
- 19.23%
- ROIC
- -62.06%
Growth & Income
- Revenue
- $221.11M · 96.52%
- Net Income
- $-112,053,693 · 57.52%
- EPS
- $-0.52 · 64.14%
- Op Income
- $-116,381,000
- FCF YoY
- 56.97%
Performance & Tape
- 52W High
- $5.82
- 52W Low
- $1.68
- 50D MA
- $4.53
- 200D MA
- $4.52
- Beta
- 1.66
- Avg Volume
- 492
Get TickerSpark's AI analysis on IDRSF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IDRSF Coverage
We haven't published any research on IDRSF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IDRSF Report →